The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
Open accessAbstract
BACKGROUND: Patients with pancreatic cancer have a poor prognosis apart from the few suitable for surgery. Photodynamic therapy (PDT) produces localised tissue necrosis but previous studies using the photosensitiser meso-tetrahydroxyphenylchlorin (mTHPC) caused prolonged skin photosensitivity. This study assessed a shorter acting photosensitiser, verteporfin. METHODS: Fifteen inoperable patients with locally advanced cancers were sensitised with 0.4 mg kg(-1) verteporfin. After 60-90 min, laser light (690 nm) was delivered via single (13 patients) or multiple (2 patients) fibres positioned percutaneously under computed tomography (CT) guidance, the light dose escalating (initially 5 J, doubling after each three patients) until 12 mm of necrosis was achieved consistently. RESULTS: In all, 12 mm lesions were seen consistently at 40 J, but with considerable variation in necrosis volume (mean volume 3.5 cm(3) at 40 J). Minor, self-limiting extrapancreatic effects were seen in multifibre patients. No adverse interactions were seen in patients given chemotherapy or radiotherapy before or after PDT. After PDT, one patient underwent an R0 Whipple's pancreaticoduodenectomy. CONCLUSIONS: Verteporfin PDT-induced tumour necrosis in locally advanced pancreatic cancer is feasible and safe. It can be delivered with a much shorter drug light interval and with less photosensitivity than with older compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
Sant, M., Allemani, C., Santaquilani, M., Knijn, A., Marchesi, F., & Capocaccia, R. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.018 · Cited by 1,021
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 823
Mukherjee, S., Hurt, C. N., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., Crosby, T., Jephcott, C., Roy, R., Radhakrishna, G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70021-4 · Cited by 355
Photodynamic therapy for cancer of the pancreas
Bown, S. G., Rogowska, A. Z., Whitelaw, D. E., Lees, W. R., Lovat, L. B., Ripley, P., Jones, L., Wyld, P., Gillams, A., & Hatfield, A. W. R. (2002) · Gut · doi:10.1136/gut.50.4.549 · Cited by 335
Self-citationIrreversible Electroporation Therapy in the Management of Locally Advanced Pancreatic Adenocarcinoma
Martin, R. C. G., McFarland, K., Ellis, S., & Velanovich, V. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2012.05.021 · Cited by 287
Narayanan, G., Hosein, P. J., Arora, G., Barbery, K. J., Froud, T., Livingstone, A. S., Franceschi, D., Rocha Lima, C. M., & Yrizarry, J. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.09.012 · Cited by 230
Cited by
Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine
Overchuk, M., Weersink, R. A., Wilson, B. C., & Zheng, G. (2023) · ACS Nano · doi:10.1021/acsnano.3c00891 · Cited by 1,323
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Van Straten, D., Mashayekhi, V., De Bruijn, H., Oliveira, S., & Robinson, D. (2017) · Cancers · doi:10.3390/cancers9020019 · Cited by 1,012
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Clinical development of photodynamic agents and therapeutic applications
Baskaran, R., Lee, J., & Yang, S.-G. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0140-z · Cited by 564
Photodynamic therapy (PDT) of cancer: from local to systemic treatment
Dabrowski, J. M., & Arnaut, L. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00132c · Cited by 501
Metadata
- Authors
- Huggett, M. T., Jermyn, M., Gillams, A., Illing, R., Mosse, S., Novelli, M., Kent, E., Bown, S. G., Hasan, T., Pogue, B. W., & Pereira, S. P.
- Venue
- British Journal of Cancer
- Published
- 2014-02-25
- Volume
- 110
- Issue
- 7
- Pages
- 1698-1704
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2013316743
- Cited by
- 396
- References
- 26
- FWCI
- 20.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. https://app.cochat.ai/papers/10.1038/bjc.2014.95
- The paper
- Huggett, M. T., Jermyn, M., Gillams, A., Illing, R., Mosse, S., Novelli, M., Kent, E., Bown, S. G., Hasan, T., Pogue, B. W., & Pereira, S. P. (2014). Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2014.95
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.